5326122025-01-012025-03-315326122025-03-315326122024-03-315326122024-04-012025-03-315326122025-01-012025-03-31in-capmkt:OtherExpenses1Member5326122025-01-012025-03-31in-capmkt:OtherExpenses2Member5326122024-04-012025-03-31in-capmkt:OtherExpenses1Member5326122024-04-012025-03-31in-capmkt:OtherExpenses2Member5326122025-01-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122024-04-012025-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15326122025-01-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15326122024-04-012025-03-31ItemsThatWillBeReclassifiedToProfitAndLoss15326122025-01-012025-03-31AuditorDomain1iso4217:INRiso4217:INRxbrli:shares532612INDOCONOTLISTEDINE873D01024INDOCO REMEDIES LIMITEDMain BoardEquity2024-04-012025-03-312025-05-222025-05-14INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2025-05-2212:56:002025-05-2214:25:00trueCash Flow IndirectDeclaration of unmodified opinion2025-01-012025-03-31AuditedConsolidated3902100000202000003922300000858600000306200000-105100000106360000017980000028780000017866000004377500000-4552000000-455200000-27000000-14800000-418000000-4134000000000-413400000-29300000-442700000-403900000-9500000-433200000-95000001845000002-4.48-4.4800-4.48-4.481. The Audited Consolidated Results for the Quarter and Year ended 31st March,2025, have been reviewed by the Audit Committee and approved by the Board of Director of the Company at its meeting held on 22nd May, 2025. The Statutory Auditors have expressed an Unmodified Audit opinion on these audited Consolidated Financial Results. <BR> <BR> 2. The figures for corresponding previous periods have been restated / regrouped wherever necessary, to make them comparable. <BR> <BR> 3. The Board of Directors have proposed, subject to the approval of shareholders in the ensuing Annual General Meeting a Dividend of 10% i.e. Rs. 0.20 per equity share on face value of Rs. 2/-each to its equity shareholder's for the year 2024-2025. <BR> <BR> 4. In Nomination and Remuneration Committee meeting held on 21st January 2025, the Company has allotted 65,700 number of equity shares to Indoco Employees Welfare Trust under Indoco Remedies Limited Employee Stock Option Plan-2022. <BR> <BR> 5. The company has only one primary reportable segment of activity, namely, Pharmaceuticals. <BR> <BR> 6. Net Sales and Income from Operations as per Secondary Segment (Geographical) is as follows: <BR> (Rs. in lakhs) <BR> Net Sales ands Quarter ended Quarter ended Quarter ended Year ended Year ended <BR> Income from 31.03.2025 31.12.2024 31.03.2024 31.03.2025 31.03.2024 <BR> Operations Audited Unaudited Audited Audited Audited <BR> <BR> India 26,186 28,162 22,451 1,09,039 96,758 <BR> Outside India 12,203 12,083 21,457 55,090 82,064 <BR> Total 38,389 40,245 43,908 1,64,129 1,78,822 <BR> <BR> 7. The Consolidated Financial Results includes the Results of the following Companies <BR> <BR> Name of the Company % of Shareholdings Consolidated as <BR> Xtend Industrial Designers & Engineers Pvt Ltd 100 Subsidiary <BR> Indoco Remedies Czech S R O 100 Subsidiary <BR> Indoco Remedies UK Ltd 100 Subsidiary <BR> Warren Remedies Private Ltd 100 Subsidiary <BR> FPP Holding Company, LLC 85 Subsidiary <BR> <BR> 8. Figures for the quarter ended 31.3.2025 and 31.3.2024 represents the difference between audited figures in respect of the full financial year and published figures for the period ended 31.12.2024 (limited reviewed) and 31.12.2023 (limited reviewed). <BR> <BR> 9. Exceptional items include consideration received Rs 99.4 lacs for grants to use exclusive, perpetual and irrevocable license rights in respect of trademarks of the company. <BR> 2024-04-012025-03-31AuditedConsolidated16649200000545000001670370000039627000001409300000-39020000039405000006623000001138400000673430000017457300000-7536000009900000-743700000470000031100000358000000-7795000000000-779500000-41300000-820800000-737400000-42100000-778700000-421000001845000002100355000008.468.45008.468.45Research & Development Expenses173900000Other Expenses1612700000Research & Development Expenses760100000Other Expenses5974200000849060000027612000002152000001263000000444200000146000003610000062400000113100000998400000142857000004193500000035241000001210000004970000033100000334000003761300000184100000187450000010013400000242991000001845000001003550000010220000000-36200000101838000005425600000439000005469500000358200000133600000741000006035400000451000000055900000015223000002081300000805500000739680000023160000045150000080799000001411530000024299100000662300000-6629000005065000000-338300000-4800000-200000180000000545700000086800000011384000000-32200000-39000000-87000000352000001550000008400000220000000008200000-160000001864200000112050000000017120000009493000000079000000000003800000035615000000000000000000000008400000045000000-33911000000001590000000002642900000-58580000052300000139000000639100000002414200000-276000000-27600000148600000121000000Items that will not be reclassified to profit & loss-51400000-51400000Items that will not be reclassified to profit & loss-60400000-60400000-12900000-15200000Items that may be reclassified to profit & loss1030000010300000Items that may be reclassified to profit & loss330000033000001100000-600000-29300000-41300000AuditedtrueGokhale and Sathetrue2027-02-28